Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Attack
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 165 results found since Jan 2013.
08.02.17: Not intended for U.S. and UK Media
Phase III COMPASS study with Bayer's Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early Coronary or peripheral artery disease patients carry significant risk of fatal or debilitating myocardial infarction and stroke / Rivaroxaban is the only non-vitamin K antagonist oral anticoagulant currently under assessment in this high risk patient populationmehr ...
Source: Bayer IR Newsfeed: Events - February 7, 2017 Category: Pharmaceuticals Source Type: news
Amgen announces Repatha ® (evolocumab) significantly reduced the risk of cardiovascular events in FOURIER outcomes study
Amgen (NASDAQ:AMGN) has announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke).
Source: World Pharma News - February 3, 2017 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
Amgen Announces Repatha ® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Landmark Repatha Cardiovascular Outcomes Study Meets Primary and Key Secondary Endpoint
Detailed Results to be Presented at ACC 66th Annual Scientific Session
THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and ...
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Warns ABX Weight Loss Has Hidden Danger
ABX Weight Loss contains sibutramine, a controlled substance that was removed from the market in October 2010, and could lead to heart attack and stroke
Source: PharmaManufacturing.com - November 16, 2016 Category: Pharmaceuticals Source Type: news
Study Suggests Heart Patients May Need Fewer Blood Thinners
Researchers said a study involving reduced doses of Johnson& Johnson ’s anticoagulant Xarelto suggests it may be possible for patients with two types of heart disease to avoid the need for three different blood thinners to protect them from stroke and heart attack.
Source: WSJ.com: Health - November 15, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news
Amgen Researchers Find Gene That Reduces Heart Attack Risk
Researchers at DeCode Genetics, an Icelandic unit of the biotechnology firm Amgen, have identified a new genetic variant that reduces the risk of heart disease and stroke by 34%.
Source: Forbes.com Healthcare News - May 18, 2016 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
'Mediterranean' diet linked to lower risk of heart attacks & strokes in heart patients
A "Mediterranean" diet, high in fruit, vegetables, fish and unrefined foods, is linked to a lower risk of heart attack and stroke in people who already have heart disease, according to a study of over 15,000 people in 39 countries around the world. The research also showed that eating greater amounts of healthy food was more important for these people than avoiding unhealthy foods, such as refined grains, sweets, desserts, sugared drinks and deep-fried food - a "Western" diet.
Source: World Pharma News - April 27, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Does Money From Pharma Companies Make Physicians Prescribe Pricey Medications?
When your doctor tells you that you should take a new medication, you want to trust that she has your best interests in mind. You certainly don’t want to think that she is allowing her own financial interests to influence her prescribing decisions. Take for instance the decision to prescribe brand-name drugs versus generics. When you have high cholesterol and your doctor prescribed an expensive brand-name statin, is she doing that because she believes that drug is the best one to prevent you from experiencing a heart attack or stroke? Or is she doing it because she feels obligated to the company that manufactures the drug?
Source: Forbes.com Healthcare News - April 8, 2016 Category: Pharmaceuticals Authors: Peter Ubel Source Type: news
Diabetes drug may prevent recurring strokes
Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) trial, presented at the International Stroke Conference 2016 in Los Angeles and published in the New England Journal of Medicine, suggest a potential new method to prevent stroke and heart attack in high-risk patients who have already had one stroke or transient ischemic attack.
Source: World Pharma News - February 18, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Testosterone Lawsuit News Update from National Law Firm
Attorneys representing persons involved in national testosterone lawsuits for heart attack and stroke allegations at the Onder Law Firm provide regular news updates on the pending testosterone...(PRWeb September 18, 2015)Read the full story at http://www.prweb.com/releases/testosterone-lawsuit/heart-attack-attorneys/prweb12968566.htm
Source: PRWeb: Medical Pharmaceuticals - September 19, 2015 Category: Pharmaceuticals Source Type: news
The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot
The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins.
Source: Forbes.com Healthcare News - July 24, 2015 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
FDA Strengthens NSAIDs Heart Attack, Stroke Warning
Based on the FDA's comprehensive review of new safety information, the agency is strengthening an existing label warning that NSAIDs increase the chance of a heart attack or stroke.
Source: PharmaManufacturing.com - July 14, 2015 Category: Pharmaceuticals Source Type: news
FDA Strengthens Warnings on Class of Painkillers
The FDA strengthened its safety warnings about heart-attack and stroke risks linked to a class of common pain relievers that includes medicines such as Celebrex, Advil, Motrin IB and Aleve.
Source: WSJ.com: Health - July 10, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news
Testosterone Lawsuit News: July Conference on Bellweather Trials
Attorneys handling national testosterone lawsuits alleging heart attack and stroke anticipate upcoming Case Management Conference in the national testosterone lawsuit multidistrict litigation,...(PRWeb June 30, 2015)Read the full story at http://www.prweb.com/releases/testosterone-lawsuit-news/heart-attack-stroke/prweb12821876.htm
Source: PRWeb: Medical Pharmaceuticals - July 1, 2015 Category: Pharmaceuticals Source Type: news
